Literature DB >> 14432939

Guanethidine administration in 28 hypertensive patients.

G PIGEON, J DAVIGNON, P BIRON, J TRUDEL, C DUFAULT, J GENEST.   

Abstract

Entities:  

Keywords:  AMIDINES/therapy; ANTIHYPERTENSIVE AGENTS/therapy

Mesh：

Substances：

Year:  1960        PMID： 14432939      PMCID： PMC1938705     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Pharmacology of [2-(octahydro-1-azocinyl)-ethyl]-guanidine sulfate (Su-5864).

Authors:  R A MAXWELL; A J PLUMMER; F SCHNEIDER; H POVALSKI; A I DANIEL
Journal:  J Pharmacol Exp Ther       Date:  1960-01       Impact factor: 4.030

2.  A new, potent antihypertensive drug: preliminary study of [2-(octahydro-1-azocinyl)-ethyl]-guanidine sulfate (guanethidine).

Authors:  I H PAGE; H P DUSTAN
Journal:  J Am Med Assoc       Date:  1959-07-11

3.  Effective reduction in blood pressure without ganglionic blockade.

Authors:  D W RICHARDSON; E M WYSO
Journal:  Va Med Mon (1918)       Date:  1959-07

4.  Pharmacology of hexahydro-1-azepinepropionamidoxime dihydrochloride (SU-4029).

Authors:  R A MAXWELL; S D ROSS; A J PLUMMER
Journal:  J Pharmacol Exp Ther       Date:  1958-06       Impact factor: 4.030

5.  [2-Octahydro-1-azocinyl)-ethyl]-guanidine sulfate (CIBA 5864-SU), a new synthetic antithypertensive agents].

Authors:  R A MAXWELL; R P MULL; A J PLUMMER
Journal:  Experientia       Date:  1959-07-15

6.  Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent.

Authors:  R CASS; R KUNTZMAN; B B BRODIE
Journal:  Proc Soc Exp Biol Med       Date:  1960-04
  6 in total
  2 in total

1.  [ASPERMATISM AFTER PERORAL ADMINISTRATION OF GUANETHIDINE].

Authors:  W KIESSLING; K HUHNSTOCK
Journal:  Klin Wochenschr       Date:  1963-10-01

2.  Long-Term Follow-up of Patients with Hypertensive Disease Treated with Guanethidine.

Authors:  J A Lewis; D A Kavelman
Journal:  Can Med Assoc J       Date:  1963-05-18       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.